Macro-vasculature: A Novel Image Biomarker of Lung Cancer
大血管系统:肺癌的新型图像生物标志物
基本信息
- 批准号:10292493
- 负责人:
- 金额:$ 23.15万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-01-13 至 2023-01-01
- 项目状态:已结题
- 来源:
- 关键词:AchievementAdenocarcinomaAdultAgeAppearanceBenignBiopsyBlood VesselsBody CompositionCancer EtiologyCancer ModelCancer PatientCessation of lifeCharacteristicsChestChinese PeopleClinicalClinical ManagementCollaborationsComputersData SetDatabasesDetectionDevelopmentDiagnostic ProcedureDiseaseEarly DiagnosisEnsureExcisionFunding OpportunitiesGenderGoalsGrowthHealthcareHigh Resolution Computed TomographyImageIncidenceInstitutionInterventionInvestigationLeadLobarLungLung AdenocarcinomaLung NeoplasmsLung noduleMachine LearningMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of lungMetastatic Neoplasm to Lymph NodesMetastatic Neoplasm to the LungMorbidity - disease rateMorphologyNoduleNutrientOperative Surgical ProceduresOutcomeOxygenPathologicPathologyPatientsPositron-Emission TomographyProceduresProcessQuality of lifeRadiation exposureRadiation therapyRecording of previous eventsReportingResearchRiskScanningSelection for TreatmentsSmokerTechnologyTestingTextureThoracic RadiographyTimeTobacco smoking behaviorTreatment outcomeUnited StatesUnited States National Institutes of HealthVisualWithholding TreatmentX-Ray Computed Tomographyaccurate diagnosisalgorithm developmentbasecancer diagnosiscancer invasivenesscancer therapycare burdenclinical practiceclinical translationcomputerizedexperiencefollow-upimaging biomarkerimprovedinterestlow dose computed tomographylung basal segmentlung cancer screeningmortalitymultidisciplinarynovelprogramsracial differenceradiomicsscreeningside effectsmoking cessationsuccesstooltranslational clinical trialtreatment planningtumor
项目摘要
ABSTRACT
Lung cancer remains the leading cause of cancer related deaths in the United States and worldwide despite
advances in early detection, treatment, and smoking cessation programs. It was reported by the National Lung
Screening Trial (NLST) that screening with low dose computed tomography (LDCT) scans may reduce lung
cancer mortality by 20% compared to chest x-ray. This conclusion ultimately led to the approval and
reimbursement for lung cancer screening using LDCT among asymptomatic adults with a history of tobacco
smoking. However, LDCT-based screening often results in a large number of indeterminate nodules that later
turn out to be non-cancerous. With increasing implementation of LDCT-based lung cancer screening in the U.S.,
the detection of indeterminate lung nodules during lung cancer screening is likely to increase. To reduce
unnecessary diagnostic procedures, such as follow-up CT scan, positron emission tomography (PET)/CT exam,
and invasive biopsies, a tool that can easily and accurately assess the malignancy and invasiveness of the
indeterminate findings will be a welcomed addition to clinical practice. Different levels of invasiveness typically
indicate different treatment plans and can often predict the treatment outcome. Compared to the investigative
efforts dedicated to discriminating benign from malignant nodules, very limited effort has been focused on
assessing the invasiveness of the suspicious nodules and explore the underlying factors associated with
invasiveness. We proposed to develop and validate a novel computer tool to non-invasively assess the
invasiveness of adenocarcinomas using LDCT scans from a large and diverse lung cancer database with
pathology outcome. We will investigate and identify how image-based features contribute to invasiveness. Our
exciting preliminary results demonstrate the feasibility of developing and implementing such a tool and its highly
translational potential. We believe that our computer tool will be a tremendously useful addition to the clinical
practice of lung cancer diagnosis and treatment. Its availability will: (1) enable a timely and accurate diagnosis
of lung cancer, (2) limit the need for further imaging, biopsies, and possible surgery, and (3) facilitate an optimal
selection of the treatment approach (e.g., surgical resection or radiotherapy). Ultimately, we want to improve
survival and the quality of life of lung cancer patients.
摘要
肺癌仍然是美国和世界范围内与癌症相关的死亡的主要原因,尽管
早期发现、治疗和戒烟计划的进展。据《国家肺报》报道,
使用低剂量计算机断层扫描(LDCT)进行筛查的筛查试验(NLST)可能会减少肺部
与胸部X光相比,癌症死亡率降低了20%。这一结论最终导致了对
有吸烟史的无症状成年人中使用LDCT进行肺癌筛查的报销
抽烟。然而,基于LDCT的筛查通常会导致大量不确定的结节,随后
结果证明是非癌症的。随着美国越来越多地实施基于LDCT的肺癌筛查,
在肺癌筛查中,不确定肺结节的检测可能会增加。减少
不必要的诊断程序,如后续CT扫描、正电子发射断层扫描(PET)/CT检查,
和侵入性活检,这是一种可以轻松准确地评估肿瘤的恶性度和侵袭性的工具
不确定的发现将是临床实践中受欢迎的补充。不同级别的入侵通常
提示不同的治疗计划,通常可以预测治疗结果。与调查性的
致力于区分良性和恶性结节的努力,一直集中在非常有限的努力上
评估可疑结核的侵袭性,并探讨与之相关的潜在因素
侵犯性。我们建议开发和验证一种新的计算机工具来非侵入性地评估
用LDCT扫描从大型和多样化的肺癌数据库中评估腺癌的侵袭性
病理结果。我们将调查并确定基于图像的特征是如何导致入侵的。我们的
令人振奋的初步结果证明了开发和实施这样一个工具的可行性和高度的
翻译潜力。我们相信,我们的计算机工具将是临床上非常有用的补充
肺癌诊疗实习。它的可用性将:(1)实现及时和准确的诊断
肺癌,(2)限制进一步的成像、活检和可能的手术的需要,以及(3)促进最佳的
治疗方法的选择(如手术切除或放射治疗)。最终,我们想要改进
肺癌患者的生存和生活质量。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jiantao Pu其他文献
Jiantao Pu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jiantao Pu', 18)}}的其他基金
Macro-vasculature: A Novel Image Biomarker of Lung Cance
大血管系统:肺癌的新型图像生物标志物
- 批准号:
10311064 - 财政年份:2020
- 资助金额:
$ 23.15万 - 项目类别:
Macro-vasculature: A Novel Image Biomarker of Lung Cance
大血管系统:肺癌的新型图像生物标志物
- 批准号:
9883874 - 财政年份:2020
- 资助金额:
$ 23.15万 - 项目类别:
Macro-vasculature: A Novel Image Biomarker of Lung Cance
大血管系统:肺癌的新型图像生物标志物
- 批准号:
10536597 - 财政年份:2020
- 资助金额:
$ 23.15万 - 项目类别:
CT Assessment of Lung Fissures: Anatomy and Correlated Function
肺裂的 CT 评估:解剖结构和相关功能
- 批准号:
7881830 - 财政年份:2010
- 资助金额:
$ 23.15万 - 项目类别:
CT Assessment of Lung Fissures: Anatomy and Correlated Function
肺裂的 CT 评估:解剖结构和相关功能
- 批准号:
8456152 - 财政年份:2010
- 资助金额:
$ 23.15万 - 项目类别:
CT Assessment of Lung Fissures: Anatomy and Correlated Function
肺裂的 CT 评估:解剖结构和相关功能
- 批准号:
8066017 - 财政年份:2010
- 资助金额:
$ 23.15万 - 项目类别:
CT Assessment of Lung Fissures: Anatomy and Correlated Function
肺裂的 CT 评估:解剖结构和相关功能
- 批准号:
9204412 - 财政年份:2010
- 资助金额:
$ 23.15万 - 项目类别:
CT Assessment of Lung Fissures: Anatomy and Correlated Function
肺裂的 CT 评估:解剖结构和相关功能
- 批准号:
8257535 - 财政年份:2010
- 资助金额:
$ 23.15万 - 项目类别:
相似国自然基金
大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
- 批准号:30840003
- 批准年份:2008
- 资助金额:12.0 万元
- 项目类别:专项基金项目
相似海外基金
Synergistic Radiosensitization of Hypoxic Pancreatic Adenocarcinoma using Gd-Texaphyrin Oxygen-Loaded Nanodroplets
使用 Gd-Texaphyrin 载氧纳米液滴对缺氧胰腺腺癌进行协同放射增敏
- 批准号:
478914 - 财政年份:2023
- 资助金额:
$ 23.15万 - 项目类别:
Operating Grants
Expression mechanism of immune checkpoint molecules after carbon-ion radiotherapy in cervical adenocarcinoma specimens
宫颈腺癌碳离子放疗后免疫检查点分子的表达机制
- 批准号:
23K14913 - 财政年份:2023
- 资助金额:
$ 23.15万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Study of fibrosis in pancreatic ductal adenocarcinoma (PDAC) and application of adipose-derived stromal/stem cells for PDAC treatment
胰腺导管腺癌(PDAC)纤维化的研究以及脂肪源性基质/干细胞在 PDAC 治疗中的应用
- 批准号:
23K15035 - 财政年份:2023
- 资助金额:
$ 23.15万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA
IRAK4 作为胰腺导管腺癌的新型免疫治疗靶点
- 批准号:
10442874 - 财政年份:2023
- 资助金额:
$ 23.15万 - 项目类别:
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
NSD2 在肺腺癌中的治疗靶向
- 批准号:
10657069 - 财政年份:2023
- 资助金额:
$ 23.15万 - 项目类别:
Control mechanisms of lung adenocarcinoma by SGLT2 inhibitors for treating diabetes mellitus.
SGLT2抑制剂治疗糖尿病对肺腺癌的控制机制。
- 批准号:
23K08326 - 财政年份:2023
- 资助金额:
$ 23.15万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Establishment of histological transformation model from lung small cell carcinoma from adenocarcinoma to explore the therapeutic strategies of small cell lung carcinoma.
建立肺小细胞癌腺癌组织学转化模型,探讨小细胞肺癌的治疗策略。
- 批准号:
23K14614 - 财政年份:2023
- 资助金额:
$ 23.15万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms of tumor progression controlled by tumor-initiating cells and cancer-associated fibroblasts in pancreatic adenocarcinoma.
阐明胰腺腺癌中肿瘤起始细胞和癌症相关成纤维细胞控制的肿瘤进展机制。
- 批准号:
23K15075 - 财政年份:2023
- 资助金额:
$ 23.15万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Molecular mechanisms for development of pulmonary invasive mucinous adenocarcinoma
肺浸润性粘液腺癌发生的分子机制
- 批准号:
23H02698 - 财政年份:2023
- 资助金额:
$ 23.15万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Elucidating the Cellular Origins of lung adenocarcinoma
阐明肺腺癌的细胞起源
- 批准号:
10743611 - 财政年份:2023
- 资助金额:
$ 23.15万 - 项目类别:














{{item.name}}会员




